Trial of Prophylactic Tamsulosin for Postoperative Urinary Retention in Primary Total Hip and Knee Arthroplasty Patients

Prophylactic administration of tamsulosin will be compared to a placebo to evaluate the
effectiveness in reducing the incidence of postoperative urinary retention in total hip and
knee arthroplasty patients.

Inclusion Criteria:

- Men age 35 or older

- Primary total hip and knee arthroplasty patients (general, spinal, or epidural
anesthesia

- No current use (>1 month) of alpha-blockers

- Community ambulator

- Adequate organ and marrow function as defined below:

leucocytes at least 3,000/µL, absolute neutrophil count at least 1,500/µL, platelets at
least 100,000/µL, creatinine within normal institutional limits

- Ability to understand, and the willingness to sign, a written informed consent

Exclusion Criteria:

- History of radical prostatectomy

- Receiving any other investigational agents

- Revision hip and knee arthroplasty patients

- Severe liver or kidney disease

- Taking strong inhibitors of CYP3A4 (ketoconazole, itraconazole, clarithromycin,
ritonavir, indinavir/ritonavir, lopinavir, or conivaptan)

- Being on alpha-blockers (alfuzosin, doxazosin, prazosin, terazosin, tamsulosin,
phenoxybenzamine, or silodosin)

- Being of 5-alpha reductase inhibitors (finasteride, dutasteride)

- History of allergy or sensitivity to tamsulosin or other alpha-blockers (alfuzosin,
doxazosin, prazosin, terazosin, or phenoxybenzamine)

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Taking Sildenafil,Tadalafil, or Vardenafil